Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KALV Kalvista Pharmaceuticals Inc

休市中 12-26 16:00:00 EST

15.17

-0.62

-3.93%

盘后15.17

+0.000.00%

18:10 EST

最高15.63	最低14.91	成交量73.20万
今开15.62	昨收15.79	日振幅4.55%
总市值7.67亿	流通市值4.22亿	总股本5,055万
成交额1,112万	换手率2.63%	流通股本2,781万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KALV","market":"US","secType":"STK","nameCN":"Kalvista Pharmaceuticals Inc","latestPrice":15.17,"timestamp":1766782800000,"preClose":15.79,"halted":0,"volume":732041,"hourTrading":{"tag":"盘后","latestPrice":15.17,"preClose":15.17,"latestTime":"18:10 EST","volume":56848,"amount":862384.0013,"timestamp":1766790611241},"delay":0,"floatShares":27812263,"shares":50546293,"eps":-3.946012,"marketStatus":"休市中","change":-0.62,"latestTime":"12-26 16:00:00 EST","open":15.62,"high":15.63,"low":14.9121,"amount":11123400.329091,"amplitude":0.045465,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.946012,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1766998800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1479790800000,"exchange":"NASDAQ","adjPreClose":15.79,"preHourTrading":{"tag":"盘前","latestPrice":15.94,"preClose":15.79,"latestTime":"09:29 EST","volume":703,"amount":11073.580076,"timestamp":1766759399999},"postHourTrading":{"tag":"盘后","latestPrice":15.17,"preClose":15.17,"latestTime":"18:10 EST","volume":56848,"amount":862384.0013,"timestamp":1766790611241},"volumeRatio":0.7988802770867264,"impliedVol":0.5607,"impliedVolPercentile":0.192},"requestUrl":"/m/hq/s/KALV","defaultTab":"news","newsList":[{"id":"1149381360","title":"Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准，成为首个也是唯一的口服按需治疗遗传性水肿的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1149381360","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149381360?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:01","pubTimestamp":1766401271,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准，成为首个也是唯一的口服按需治疗遗传性水肿的药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"1148702813","title":"Kalvista Pharmaceuticals将于2025年11月11日召开第三季度财务业绩电话会议和网络广播","url":"https://stock-news.laohu8.com/highlight/detail?id=1148702813","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148702813?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:01","pubTimestamp":1762171276,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals将于2025年11月11日召开第三季度财务业绩电话会议和网络广播","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"1104662770","title":"Kalvista Pharmaceuticals任命Bilal Arif为首席运营官，Linea Aspesi为首席人事官","url":"https://stock-news.laohu8.com/highlight/detail?id=1104662770","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104662770?lang=zh_cn&edition=full","pubTime":"2025-10-06 19:02","pubTimestamp":1759748576,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals宣布任命Bilal Arif担任公司首席运营官，同时任命Linea Aspesi为首席人事官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2567190639","title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","url":"https://stock-news.laohu8.com/highlight/detail?id=2567190639","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567190639?lang=zh_cn&edition=full","pubTime":"2025-09-13 06:38","pubTimestamp":1757716705,"startTime":"0","endTime":"0","summary":"研发新冠疫苗的BioNTech盘中跌超10%、莫德纳跌超7%、Novavax跌超4%。投资者担心，如果特朗普政府进一步收紧疫苗接种政策，可能对疫苗制造商的业务造成重大冲击，特别是对莫德纳这类高度依赖新冠疫苗收入的公司。更新中","market":"us","thumbnail":"https://static.tigerbbs.com/632b4e916ff966270173f4303843021f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/632b4e916ff966270173f4303843021f"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3755508","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ae8bc75ba4d1918dcafc0476d86c6d53","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3755508","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["NVS","SRPT","PGEN","BMY","AZN","PFE","TRVI","KALV","MRK","MRNA","BNTX","ARCT","NVAX","BK4009","PSNL","ABUS","TARS","TVTX","STRO"],"gpt_icon":1},{"id":"1157351096","title":"Kalvista Pharmaceuticals Inc将于2025年9月11日发布运营更新及财季业绩报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1157351096","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157351096?lang=zh_cn&edition=full","pubTime":"2025-09-04 19:07","pubTimestamp":1756984059,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals Inc将于2025年9月11日发布运营更新及财季财务业绩报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2555706795","title":"Kalvista Pharmaceuticals, Inc.盘中异动 下午盘急速下挫5.14%报13.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555706795","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555706795?lang=zh_cn&edition=full","pubTime":"2025-07-29 02:53","pubTimestamp":1753728805,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日02时53分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.14%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Celcuity Inc.、Protagenic Therapeutics Inc C/Wts 26/04/2026 、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Aim Immunotech Inc.、Tnf Pharmaceuticals, Inc.、Cervomed Inc.较为活跃，换手率分别为559.15%、322.30%、134.98%，振幅较大的相关个股有Aim Immunotech Inc.、Celcuity Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 ，振幅分别为158.93%、82.93%、75.48%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家制药公司，为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729025326a4682979&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729025326a4682979&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B64QTZ34.USD","HAE","LU0205194284.USD","LU0205193047.USD","LU1169589451.USD","BK4198","LU1169590202.USD","BK4139","IE00BLDYK493.USD","KALV","LU0012050646.USD","LU0106261612.USD"],"gpt_icon":0},{"id":"1117091272","title":"异动解读 | Kalvista Pharmaceuticals股价盘中大跌5.53%，财报显示亏损扩大44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117091272","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117091272?lang=zh_cn&edition=full","pubTime":"2025-07-11 21:32","pubTimestamp":1752240757,"startTime":"0","endTime":"0","summary":"周五盘中，Kalvista Pharmaceuticals Inc股价大跌5.53%，引发市场关注。这一跌势与公司同日发布的2025财年财报密切相关。根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。Kalvista Pharmaceuticals总负债为1.55亿美元，资产负债比高达1.62，流动比率仅为0.06，反映出公司当前的财务状况不容乐观。Kalvista Pharmaceuticals作为一家专注于开发小分子蛋白酶抑制剂的制药公司，其产品管线主要针对遗传性血管性水肿和糖尿病性黄斑水肿等疾病，公司的未来发展仍值得市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KALV"],"gpt_icon":0},{"id":"1100750260","title":"异动解读 | Kalvista Pharmaceuticals股价盘中大跌5.53%，2025财年净亏损扩大44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100750260","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100750260?lang=zh_cn&edition=full","pubTime":"2025-07-11 21:32","pubTimestamp":1752240743,"startTime":"0","endTime":"0","summary":"7月11日周五，Kalvista Pharmaceuticals Inc股价在盘中大跌5.53%，引起市场关注。这一显著跌幅与公司最新发布的2025财年财报密切相关。根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。从资产负债状况来看，Kalvista Pharmaceuticals的财务状况同样不容乐观。公司总负债为1.55亿美元，资产负债比高达1.62，而流动比率仅为0.06，表明公司面临较大的财务压力和流动性风险。作为一家专注于开发小分子蛋白酶抑制剂的制药公司，Kalvista Pharmaceuticals的未来发展仍值得市场持续关注。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KALV"],"gpt_icon":0},{"id":"2550367309","title":"Kalvista Pharmaceuticals, Inc.盘中异动 急速跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550367309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550367309?lang=zh_cn&edition=full","pubTime":"2025-07-11 03:32","pubTimestamp":1752175974,"startTime":"0","endTime":"0","summary":"北京时间2025年07月11日03时32分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.00%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。其相关个股中，Pelthos Therapeutics Inc.、Q32 Bio Inc.、Lixte Biotechnology Holdings, Inc.涨幅较大，Cognition Therapeutics, Inc.、Q32 Bio Inc.、Calidi Biotherapeutics, Inc.较为活跃，换手率分别为388.82%、364.36%、355.00%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Q32 Bio Inc.、Pelthos Therapeutics Inc.，振幅分别为91.19%、90.07%、85.25%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711033255a6a223e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711033255a6a223e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2550365500","title":"Kalvista Pharmaceuticals, Inc.盘中异动 股价大涨5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550365500","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550365500?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:06","pubTimestamp":1752069998,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日22时06分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.35%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.33%。其相关个股中，Calidi Biotherapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Prokidney Corp.涨幅较大，Calidi Biotherapeutics, Inc.、Kazia Therapeutics Limited、Mustang Bio, Inc.较为活跃，换手率分别为773.20%、663.13%、486.81%，振幅较大的相关个股有Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Calidi Biotherapeutics, Inc.、Prokidney Corp.，振幅分别为112.02%、59.70%、48.79%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709220638953c3cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709220638953c3cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2549580115","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升17.61%报14.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549580115","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549580115?lang=zh_cn&edition=full","pubTime":"2025-07-07 21:31","pubTimestamp":1751895105,"startTime":"0","endTime":"0","summary":"北京时间2025年07月07日21时31分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价快速拉升17.61%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Mustang Bio, Inc.、Artelo Biosciences, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Mustang Bio, Inc.、Artelo Biosciences, Inc.、Sonnet Biotherapeutics Holdings, Inc.较为活跃，换手率分别为1370.06%、744.87%、657.11%，振幅较大的相关个股有Nucana Plc、Exicure, Inc.、Cognition Therapeutics, Inc.，振幅分别为11.94%、9.29%、6.96%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707213145a43bf639&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707213145a43bf639&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"1174488880","title":"KALV新药EKTERLY获得FDA批准推出","url":"https://stock-news.laohu8.com/highlight/detail?id=1174488880","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174488880?lang=zh_cn&edition=full","pubTime":"2025-07-07 19:09","pubTimestamp":1751886597,"startTime":"0","endTime":"0","summary":"7月7日，KalVista Pharmaceuticals今日宣布，美国食品药品监督管理局 (FDA) 已批准 EKTERLY (sebetralstat)，这是一种新型血浆激肽酶抑制剂，用于治疗12岁及以上成人和儿童患者的遗传性血管水肿 (HAE) 的急性发作。EKTERLY 是治疗 HAE 的首个也是唯一的按需口服治疗。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"457e5155343c7add159927f3445e8326","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"KALV新药EKTERLY获得FDA批准推出","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"1118078357","title":"盘前异动｜APGE飙升逾50%，新药试验取得积极结果；KALV大涨逾35%，新药获得FDA批准推出","url":"https://stock-news.laohu8.com/highlight/detail?id=1118078357","media":"老虎资讯综合","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118078357?lang=zh_cn&edition=full","pubTime":"2025-07-07 18:56","pubTimestamp":1751885774,"startTime":"0","endTime":"0","summary":"7月7日，美股盘前时段，APGE一度飙升逾50%，新药试验取得积极结果；KALV一度大涨逾35%，新药获得FDA批准推出；Wolfspeed续涨逾30%，上一交易日暴涨近53%。","market":"us","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"457e5155343c7add159927f3445e8326","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","WOLF","KALV"],"gpt_icon":0},{"id":"2548886370","title":"Kalvista Pharmaceuticals, Inc.盘中异动 股价大涨5.17%报11.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548886370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548886370?lang=zh_cn&edition=full","pubTime":"2025-07-02 00:20","pubTimestamp":1751386848,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日00时20分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.17%。截至发稿，该股报11.89美元/股，成交量34.8942万股，换手率0.70%，振幅5.75%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.43%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702002048a4c956bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702002048a4c956bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2546740471","title":"Kalvista Pharmaceuticals, Inc.盘中异动 股价大涨5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546740471","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546740471?lang=zh_cn&edition=full","pubTime":"2025-06-27 23:57","pubTimestamp":1751039866,"startTime":"0","endTime":"0","summary":"北京时间2025年06月27日23时57分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.78%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.26%。其相关个股中，Inmune Bio Inc.、Eyenovia, Inc.、天境生物涨幅较大，Inmune Bio Inc.、Hcw Biologics Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为164.35%、160.92%、102.94%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Channel Therapeutics Corporation、Inmune Bio Inc.，振幅分别为74.75%、64.91%、49.68%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627235746952e4ce8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627235746952e4ce8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2517985069","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.11%报11.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517985069","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517985069?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:27","pubTimestamp":1741120066,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时27分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.11%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Rapport Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.、Windtree Therapeutics, Inc.较为活跃，换手率分别为1330.19%、1258.60%、1224.41%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Plus Therapeutics, Inc.，振幅分别为122.48%、68.89%、68.09%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504274696399744&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504274696399744&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2516637427","title":"Citizens Capital Markets：重申KalVista Pharma(KALV.US)评级，由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637427","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516637427?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:11","pubTimestamp":1741014689,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申KalVista Pharma(KALV.US)评级，由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03231148494584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KALV"],"gpt_icon":0},{"id":"2516148371","title":"Kalvista Pharmaceuticals, Inc.盘中异动 急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516148371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516148371?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:36","pubTimestamp":1740760606,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时36分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.08%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Bioxcel Therapeutics, Inc.、Camp4 Therapeutics Corporation、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2922.48%、491.11%、364.17%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、46.60%、43.95%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010036479634359a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010036479634359a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2514542788","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅上涨5.06%报11.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514542788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514542788?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:38","pubTimestamp":1740584333,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时38分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.06%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5229.01%、197.73%、185.00%，振幅较大的相关个股有Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Humacyte Inc C/Wts 27/08/2026 ，振幅分别为161.02%、43.31%、39.47%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262338539893b7af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262338539893b7af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2513921966","title":"Kalvista Pharmaceuticals, Inc.盘中异动 快速下跌5.45%报10.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513921966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513921966?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:54","pubTimestamp":1740164096,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时54分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.45%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Revolution Medicines Inc C/Wts 17/12/2026 、Invivyd, Inc.涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为293.98%、247.56%、136.47%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025456962bb494&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025456962bb494&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kalvista.com","stockEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.0759},{"period":"3month","weight":0.2234},{"period":"6month","weight":0.3295},{"period":"1year","weight":0.718},{"period":"ytd","weight":0.791}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0156},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1226},{"period":"1year","weight":0.148},{"period":"ytd","weight":0.1778}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"KalVista Pharmaceuticals, Inc.于2004年3月26日在特拉华州注册成立。该公司是一家临床阶段制药公司，专注于发现、开发和商业化小分子蛋白酶抑制剂，用于有重大未满足需求的疾病。该公司运用他们对蛋白酶的化学和生物学的洞见，开发出具有高选择性、效力和生物利用度的口服疗法，该公司相信这将使它们成为治疗疾病的成功药物。该公司利用这些能力开发了针对遗传性血管性水肿（HAE）的新型小分子血浆激肽释放酶抑制剂。该公司还在进行一项新的口服XIIa因子（“XIIa因子”）抑制剂项目的临床前开发。该公司正在初步推进这一项目，以提供下一代HAE疗法，这也为将来扩展到其他未满足的高需求适应症提供了机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.015737},{"month":2,"riseRate":0.555556,"avgChangeRate":0.181118},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.059731},{"month":4,"riseRate":0.444444,"avgChangeRate":0.0305},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.040416},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.005524},{"month":7,"riseRate":0.555556,"avgChangeRate":0.039581},{"month":8,"riseRate":0.555556,"avgChangeRate":0.149368},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.065906},{"month":10,"riseRate":0.333333,"avgChangeRate":0.007901},{"month":11,"riseRate":0.555556,"avgChangeRate":0.074914},{"month":12,"riseRate":0.5,"avgChangeRate":0.042124}],"exchange":"NASDAQ","name":"Kalvista Pharmaceuticals Inc","nameEN":"Kalvista Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kalvista Pharmaceuticals Inc(KALV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kalvista Pharmaceuticals Inc,KALV,Kalvista Pharmaceuticals Inc股票,Kalvista Pharmaceuticals Inc股票老虎,Kalvista Pharmaceuticals Inc股票老虎国际,Kalvista Pharmaceuticals Inc行情,Kalvista Pharmaceuticals Inc股票行情,Kalvista Pharmaceuticals Inc股价,Kalvista Pharmaceuticals Inc股市,Kalvista Pharmaceuticals Inc股票价格,Kalvista Pharmaceuticals Inc股票交易,Kalvista Pharmaceuticals Inc股票购买,Kalvista Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kalvista Pharmaceuticals Inc(KALV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}